Novel macrocyclic HCV NS3 protease inhibitors derived from α-amino cyclic boronates

This publication has 23 references indexed in Scilit:

• Preclinical Characteristics of the Hepatitis C Virus NS3/4A Protease Inhibitor ITMN-191 (R7227)
  Antimicrobial Agents and Chemotherapy, 2008
• Structure–activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350
  Bioorganic & Medicinal Chemistry Letters, 2008
• Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
  Accounts of Chemical Research, 2008
• Discovery of (1R,5S)-N-[3-Amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a Selective, Potent, Orally Bioavailable Hepatitis C Virus NS3 Protease Inhibitor: A Potential Therapeutic Agent for the Treatment of Hepatitis C Infection
  Journal of Medicinal Chemistry, 2006
• VX-950, a Novel Hepatitis C Virus (HCV) NS3-4A Protease Inhibitor, Exhibits Potent Antiviral Activities in HCV Replicon Cells
  Antimicrobial Agents and Chemotherapy, 2006
• Preclinical Profile of VX-950, a Potent, Selective, and Orally Bioavailable Inhibitor of Hepatitis C Virus NS3-4A Serine Protease
  Antimicrobial Agents and Chemotherapy, 2006
• Hepatitis C treatment update
  The American Journal of Medicine, 2004
• Structure−Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061
  Journal of Medicinal Chemistry, 2004
• Clinical consequences of hepatitis C virus infection
  Reviews in Medical Virology, 2002
• Therapy of hepatitis C: Overview
  Hepatology, 1997